Cargando…

Anticoagulants: A Review of the Pharmacology, Dosing, and Complications

Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis. Unfractionated heparin, low molecular weight heparin, fondaparinux, and warfarin have been studied and employed extensively with direct thrombin inhibitors typically reserved for patients with complications or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alquwaizani, Mohammed, Buckley, Leo, Adams, Christopher, Fanikos, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Current Science Inc. 2013
Materias:	Thrombosis (D Slattery, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654192/ https://www.ncbi.nlm.nih.gov/pubmed/23687625 http://dx.doi.org/10.1007/s40138-013-0014-6

Ejemplares similares

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

Stability of alteplase for ultrasound-facilitated catheter-directed thrombolysis
por: Fanikos, John, et al.
Publicado: (2021)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

The Impact of Degree of Anticoagulation on Thrombotic and Other Complications in Hospitalized COVID-19 Patients
por: Zheng, Rena, et al.
Publicado: (2021)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta‐analysis
por: Horner, Daniel, et al.
Publicado: (2019)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action
por: Noordermeer, Tessa, et al.
Publicado: (2021)

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
por: Seelig, Jaap, et al.
Publicado: (2020)

Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa
por: Heitmeier, Stefan, et al.
Publicado: (2022)

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
por: Wiegers, Hanke M. G., et al.
Publicado: (2021)

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma
por: Kaptein, Fleur H. J., et al.
Publicado: (2022)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Profiling of warfarin pharmacokinetics‐associated genetic variants: Black Africans portray unique genetic markers important for an African specific warfarin pharmacogenetics‐dosing algorithm
por: Ndadza, Arinao, et al.
Publicado: (2021)

Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia
por: Tuleja, Aleksandra, et al.
Publicado: (2022)

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
por: Carney, Brian J., et al.
Publicado: (2021)

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples
por: Baker, Steven Andrew, et al.
Publicado: (2021)

Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis
por: Candeloro, Matteo, et al.
Publicado: (2022)

Barriers to integrating direct oral anticoagulants into anticoagulation clinic care: A mixed‐methods study
por: Barnes, Geoffrey D., et al.
Publicado: (2018)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

D‐dimer to rule out venous thromboembolism during pregnancy: A systematic review and meta‐analysis
por: Bellesini, Marta, et al.
Publicado: (2021)

Postinterventional antithrombotic management after venous stenting of the iliofemoral tract in acute and chronic thrombosis: A systematic review
por: Notten, Pascale, et al.
Publicado: (2021)

Pharmacology of anticoagulants used in the treatment of venous thromboembolism
por: Nutescu, Edith A., et al.
Publicado: (2016)

Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
por: Wiegers, Hanke M. G., et al.
Publicado: (2022)

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin
por: Boonyawat, Kochawan, et al.
Publicado: (2021)

The intestinal microbiome potentially affects thrombin generation in human subjects
por: Mohammed, Yassene, et al.
Publicado: (2019)

Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower‐leg injury or knee arthroscopy
por: Mohammed, Yassene, et al.
Publicado: (2022)

An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta‐analysis
por: Forgo, Gabor, et al.
Publicado: (2021)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

Low Rate of Thrombosis in Mexican Patients with COVID-19 Infection. a Benefit of Higher Doses Anticoagulants or a Sub Diagnosis?
por: Marquez, Félix Gibrant, et al.
Publicado: (2020)

Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism
por: Nutescu, Edith A., et al.
Publicado: (2016)

The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
por: Smith, Christopher W., et al.
Publicado: (2022)

Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C
por: Jiang, Miao, et al.
Publicado: (2022)

Ruling out lupus anticoagulants with mixing test–specific cutoff assessment and the index of circulating anticoagulant
por: Kumano, Osamu, et al.
Publicado: (2019)

Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism
por: Frischmuth, Tobias, et al.
Publicado: (2022)

Management of anticoagulation for cancer‐associated thrombosis in patients with thrombocytopenia: A systematic review
por: Samuelson Bannow, Bethany R., et al.
Publicado: (2018)

Impaired factor V–related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations
por: Shimonishi, Naruto, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pu4uq16ej7b6cg7cbuarbtj2di